Xconomy

SEPTEMBER 30, 2020

Ovid Therapeutics and Takeda Pharmaceutical joined forces three years ago to develop a small molecule into a potential epilepsy drug. That research is starting to pay off as the companies now look ahead to pivotal studies testing that compound in several inherited forms of the disorder.

Statistics 111

Statistics Study Report Research 111

Xconomy

JULY 2, 2018

The test, sold by Genomic Health (NASDAQ: GHDX ) of Redwood City, CA, and developed by Epic Sciences of San Diego, is for men with a dangerous, Read more » Reprints | Share: UNDERWRITERS AND PARTNERS. (Earlier this year, the federal insurance program Medicare sent positive signals about coverage but hasn’t made a final decision.)

Guide 81

Guide Study San Diego Journal 81

Xconomy

JUNE 19, 2019

Cancer immunotherapies have shown to be effective as a treatment for some cancers, but only in a fraction of patients. Oncolytics, which. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Study 61

Study Activity Develop Development 61

Xconomy

JUNE 23, 2020

Reneo Pharmaceuticals has encouraging results from an early trial of a compound it is advancing for rare diseases characterized by impaired mitochondria—our cells’ energy generators—and the company says it is now designing a large global study of its drug candidate.

San Diego 127

San Diego Study Design Develop 127

Xconomy

FEBRUARY 19, 2019

But they are nonetheless expected by the drug’s developer, Intercept Pharmaceuticals, to be good enough to support approval. Intercept (NASDAQ: ICPT ) this morning provided an interim look at a 2,370-patient NASH study known as REGENERATE.

Study 109

Study Help Marketing Develop 109

Xconomy

DECEMBER 18, 2019

More than 250 miles above the Earth’s surface aboard the International Space Station, a first-in-kind study of neurodegenerative disease is expected to reveal never-before-seen cell interactions.

Research 90

Research San Diego Study Funding 90

Xconomy

JUNE 11, 2020

The study, set to begin next month, is targeting enrollment of about 30,000 volunteers, Moderna (NASDAQ: MRNA ) announced Thursday. The main goal of the study will be preventing the symptoms of COVID-19 disease. Those patients will be randomly assigned to receive either the vaccine candidate, mRNA-1273, or a placebo.

Study 101

Study Report San Diego Research 101

Xconomy

DECEMBER 17, 2018

It can take decades and billions of dollars to develop a drug, and its fate—and often that of its developer—rests in the outcome of clinical trials. The failure of a closely-watched cancer immunotherapy combination sent ripples through the sector and led several companies to change development strategies.

Study 95

Study Develop Development San Diego 95

Xconomy

NOVEMBER 2, 2018

The gene-editing technology CRISPR-Cas9 is opening up new research avenues all the time, such as giving drug developers a cheaper, faster way to knock out genes in tumor cells. Studies of CRISPR-Cas9 to treat human disease are about to start, too. This week, we reported on a new study that raises exactly that question.

Study 74

Study Startup Research Report 74

Xconomy

APRIL 7, 2020

Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA’s OK to start testing its candidate in healthy volunteers. Those enrolled in the study will get two doses of INO-4800. Inovio (NASDAQ: INO ) said Monday it anticipated dosing its first patient that day.

San Diego 108

San Diego Study Research Develop 108

Xconomy

APRIL 9, 2020

These studies could begin as early as the end of April, assuming the companies receive regulatory clearance. The partnership pairs the mRNA vaccine technology of BioNTech (NASDAQ: BNTX ) with the vaccine and clinical trial experience of Pfizer (NYSE: PFE ).

Study 122

Study Sites Technology San Diego 122

Xconomy

APRIL 11, 2017

A $40 million transfusion led by Frazier Healthcare Partners and Denmark’s Novo A/S is bringing fresh life to a Michigan biotech working to advance a new experimental drug for treating a type of non-alcoholic fatty liver disease.

Study 55

Study San Diego Entrepreneur Venture Capital 55

Xconomy

FEBRUARY 26, 2020

Takeda (NYSE: TAK ) acquired the company for an undisclosed amount up front, plus up to $330 million in payments based on development and regulatory milestones for PvP’s experimental celiac disease drug KUMA062 (now TAK-062). The deal follows completion of a Phase 1 study evaluating the PvP drug.

San Diego 72

San Diego Study Develop Development 72

Xconomy

OCTOBER 13, 2020

Gossamer Bio’s lead drug, an experimental treatment for asthma and allergies, has failed in two mid-stage clinical trials but the biotech sees enough in the data to pursue further development in a severe form of asthma and it wants to talk with regulators about advancing the compound to a larger Phase 3 study.

San Diego 82

San Diego Study Develop Development 82

Both Sides of the Table

SEPTEMBER 15, 2022

No blog post about how Tiger is crushing everybody because it’s deploying all its capital in 1-year while “suckers” are investing over 3-years can change this reality. Anybody who has studied the VC industry knows that it works by “power law” returns in which a few key deals return the majority of a fund. It’s just math.

Venture Capital 416

Venture Capital Marketing Technical Review Seed Funding 416

Xconomy

AUGUST 22, 2016

The developer also provides rent-free space for a second EvoNexus incubator in University City (about a mile or so from UC San Diego) and a third EvoNexus incubator near UC Irvine that opened at the end of 2014. In April, a study released by the San Diego Regional Economic Development Corp.

Develop 40

Develop Development San Diego Startup 40

Xconomy

APRIL 20, 2017

San Antonio — George Perry, a scientist at the University of Texas at San Antonio, has long proposed that drug developers and researchers need to look earlier into the roots of Alzheimer’s disease. A potential discovery that targets the early development of the disease—in.

Study 68

Study Research Develop Development 68

Xconomy

APRIL 22, 2019

Swiss pharma giant Novartis has invested $75 million in a $142 million Series C round for San Diego-based Poseida, which is one of several companies developing what is meant to be a one-time, long-lasting treatment for multiple myeloma. Multiple myeloma affects about 300,000 Americans every year. While the prognosis for patients.

San Diego 83

San Diego Study Funding Invest 83

Xconomy

MAY 5, 2020

Kura Oncology is discontinuing development of one of its three clinical-stage cancer drug candidates amid pandemic-related impacts to its clinical trial plans. The company had recently landed on a recommended Phase 2 dose of KO-947, and was preparing to test it in patients with head and neck squamous cell.

San Diego 63

San Diego Study Develop Development 63

Xconomy

MARCH 28, 2019

million from new investors, including the New York-based Juvenile Diabetes Research Foundation, following the results of a clinical study of its experimental biomarker monitoring device. The company began focusing on the technology it is currently developing in 2015, Tagney said.

San Diego 103

San Diego Study Research Design 103

Xconomy

JULY 22, 2019

Acadia Pharmaceuticals’ treatment for Parkinson’s disease-related psychosis failed a Phase 3 trial that was studying use of the drug for schizophrenia patients who haven’t fully responded to existing therapies. The company announced the trial failure Monday after market close.

Study 80

Study News Marketing San Diego 80

Xconomy

AUGUST 14, 2020

The road of drug development is rife with detours and disappointments but Seres Therapeutics showed this week that course corrections can work. Four years after its microbiome therapy failed in a mid-stage study, the company reported early positive data from a pivotal test of its treatment for a type of gut infection.

Study 63

Study Course Report Company 63

Both Sides of the Table

FEBRUARY 27, 2010

There have been many studies done on the topic including looking at twins raised in separate families. There have been studies of adopted children to their natural parents versus the parents that raised them. I have also seen studies on “birth order.&#. Fred Wilson said as much on his blog also.

Startup 289

Startup Statistics Entrepreneur Study 289

Xconomy

JANUARY 9, 2019

Beta Bionics, a startup developing a medical device that monitors and manages blood sugar levels in diabetes patients, has closed $63 million to back late-stage clinical tests of its AI-powered technology. The cash tops off a Series B round of funding announced last year. Beta Bionics’s device is designed to mimic the role of.

Study 87

Study Design Capital Startup 87

Xconomy

AUGUST 22, 2019

Retrophin, the drug developer founded by jailed former biotech executive Martin Shkreli, has failed its first big test. The Retrophin (NASDAQ: RTRX ) drug flunked all of its main and secondary goals in the study, which tested fosmetpantotenate against a placebo in PKAN patients. PKAN is a lethal rare genetic.

San Diego 79

San Diego Study Marketing Develop 79

Xconomy

OCTOBER 1, 2018

The company is developing antibody drug conjugates, a class of cancer drug that links antibodies to potent cancer-fighting toxins. The new VelosBio cash is earmarked for completing the work needed to proceed into human studies. VelosBio joined Johnson & Johnson’s JLABS @ San Diego incubator in January.

San Diego 91

San Diego Incubator Class Study 91

Xconomy

APRIL 5, 2018

A Conatus Pharmaceuticals drug developed as a treatment for chronic liver disease has failed to beat a placebo in a mid-stage study, the first of four underway for the drug. The goal of the Phase 2b study was to assess whether the Conatus drug was better than a placebo at stopping or reversing.

Study 65

Study Activity Organization Develop 65

Xconomy

JUNE 13, 2019

One, headed for Phase 2 testing by next year, is being developed for mood or anxiety disorders. The other, for autism, could start a Phase 1 study in 2020. Those plans. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Tool 78

Tool Study Research Startup 78

Xconomy

DECEMBER 10, 2019

Scripps’s early-stage drug discovery division, Calibr, last year inked a big partnership with North Chicago, IL-based AbbVie (NYSE: ABBV ) to develop potential treatments for solid cancer tumors. Financial terms of this latest agreement weren’t disclosed, but the deal expands the purview.

Research 52

Research Study Design Organization 52

Xconomy

APRIL 18, 2018

The biotech, 10xBio, announced earlier this month that the FDA had approved its application to begin clinical trials in Phase 1b/2a studies testing the unnamed injectable drug. The studies are intended to establish the safety and tissue responses of the injectable drug, said Dobak, who is the chairman.

San Diego 72

San Diego Study Entrepreneur Startup 72

Xconomy

OCTOBER 7, 2019

Semenza, a professor of medicine at Johns Hopkins University, studied the gene that encodes a protein used to produce erythropoietin (EPO), a kidney. William Kaelin Jr., Sir Peter Ratcliffe, and Gregg Semenza are credited with identifying the molecular machinery that regulates the activity of genes in response to changes in oxygen levels.

Study 80

Study Activity San Diego Blogging 80

Xconomy

DECEMBER 6, 2018

An experimental attention deficit hyperactivity drug developed by SuperNus Pharmaceuticals has met the main goals of two late-stage studies , bolstering the company’s case that it could provide an alternative to currently available ADHD therapies.

Study 70

Study Develop Development San Diego 70

Xconomy

JUNE 23, 2016

San Diego’s cybersecurity workforce has grown by nearly 15 percent over the past two years, according to a study released today by the Cyber Center of Excellence, a nonprofit industry group created to boost cybersecurity jobs and technologies in the region. The center also asked the San Diego Regional Economic Development Corp.

San Diego 69

San Diego Study Outsource Development Report 69

Xconomy

NOVEMBER 3, 2017

Klotho Therapeutics , a virtual biotech developing a kidney disease treatment based on its proprietary engineered version of the human klotho enzyme, said Thursday it has raised $10 million in Series A financing from San Diego’s Thynk Capital. Studies in mice have. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

San Diego 85

San Diego Study Capital Technology 85

Xconomy

JUNE 28, 2019

Here’s a look at some recent developments, including companies moving their lead drug candidates into Phase 2 trials, new R&D partnerships, and a reminder to nominate your favorite young’un for a Biocom Catalyst award.

San Diego 56

San Diego Study Design Organization 56

Xconomy

NOVEMBER 7, 2016

Up until this point, studies of an experimental drug from Biogen and Ionis Pharmaceuticals had focused on patients with the most severe form of a rare, potentially deadly genetic disorder called spinal muscular atrophy. Biogen enrolled 126 patients in the study; 84 got nusinersen while 42 got a placebo.

Help 97

Help Study Research Statistics 97

Xconomy

DECEMBER 7, 2017

Metacrine , a biotech developing new drugs for treating chronic liver diseases and related metabolic diseases and disorders, said today it has raised $22 million in a Series B financing led by New Enterprise Associates, a new investor. Initial studies should be completed by the end of the year, the San Diego-based company said.

San Diego 49

San Diego Study Develop Development 49